Is BFLY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Software and recurring-revenue mix shift, with revenue (ttm) at ~$103M. The bear case rests on butterfly remains unprofitable, with trailing losses of roughly $76M against about $103M of revenue as of Q1 2026, so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Analysts covering it are spread from $5.25 to $11.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Butterfly remains unprofitable, with trailing losses of roughly $76M against about $103M of revenue as of Q1 2026, so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $5.25, -27.1% from the $7.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Software and recurring-revenue mix shift. Software and other services revenue grew roughly 68% year over year in Q1 2026 to about $12M and now makes up a larger share of the total. The most optimistic analyst target on BFLY is $11.00, +52.8% from the $7.20 price. That figure is only reachable if this thesis works close to its best case.

Butterfly remains unprofitable, with trailing losses of roughly $76M against about $103M of revenue as of Q1 2026, so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. The point-of-care ultrasound market is competitive, with GE HealthCare, Philips, Clarius, Exo, and others fielding rival handheld devices, which can pressure pricing and adoption. Revenue is lumpy because it leans on hardware launch cycles and large institutional orders, and the stock trades at a high multiple of sales after a large run-up, leaving it vulnerable to sharp drawdowns if growth or margins disappoint. Regulatory, reimbursement, and clinical-adoption dynamics add further uncertainty to the timeline for profitability. The most pessimistic published target is $5.25, -27.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Butterfly Network designs and sells handheld ultrasound systems built on its proprietary Ultrasound-on-Chip technology, which replaces the traditional piezoelectric crystals in an

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Software and recurring-revenue mix shift) stalling in the reported numbers rather than in the narrative, the risk above (butterfly remains unprofitable, with trailing losses of roughly $76M against about $103M of revenue as of Q1 2026, so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It makes handheld ultrasound probes built on a proprietary Ultrasound-on-Chip semiconductor, letting a single device image the whole body when plugged into a phone or tablet. It also sells subscription software, cloud storage, and AI tools that add recurring revenue on top of the hardware.

No. As of Q1 2026 the company was still posting net losses, with trailing losses of roughly $76M against about $103M of revenue. It has narrowed its adjusted-EBITDA loss and cut cash burn, but management still guides to an adjusted-EBITDA loss for full-year 2026.

Revenue grew about 25% year over year in Q1 2026 to roughly $26.5M, led by software and services up around 68%. Full-year 2026 guidance of about $117M to $121M implies roughly 20% to 24% annual growth.